|
KMID : 0854720010210030552
|
|
Korean Journal of Asthma, Allergy and Clinical Immunology
2001 Volume.21 No. 3 p.552 ~ p.560
|
|
|
Non-comparative, multicenter trial to assess the additional responses of Accolate (Zafirlukast) in persistent bronchial asthma
|
|
Park Jung-Won
Cho Young-Joo
Yoon Ho-Joo
Park Hae-Sim
Choi Byoung-Whui
Choi In-Seon
Park Choon-Sik
Min Kyung-Up
Rhee Yang-Keun
Kim Nung-Soo
Hong Chein-Soo
|
|
|
Abstract
|
|
|
Background and Objective：Accolate, one of the cysteinyl leukotriene receptor antagonists, have anti-inflammatory and bronchodilating effects. The clinical indications for LT antagonist are not yet in consensus. We performed a non-comparative multicenter trial to assess the additional responses of Accolate to the current long-term control regimens in persistent asthma.
Materials and Methods: Eighty persistent asthmatics from 10 asthma special care clinics were enrolled. Daily 20 mg of Accolate was added 2 times to the current control regimen for 6 weeks and its effects on symptom scores, morning and evening PEFR, FEV₁ and frequency of the short acting 2 agonist usage for relief of asthma were measured.
Results: The morning symptom scores significantly improved by addition of Accolate for 1 week (p$lt;0.01) and its effect persisted to the 6th week (p$lt;0.01) of trial. Nocturnal symptom scores also improved at 2nd week (p$lt;0.05) and the effect continued to the end of this trial. Days with morning asthma symptoms deceased by addition of Accolate at 4th week (p$lt;0.05) and 6th week (p$lt;0.05). The frequency of the short acting β₂- agonist inhalations significantly decreased by addition of Accolate from 1st week to the end of this trial. Morning and evening PEFR significantly improved at 1st week and the effects progressively improved to the end of this trial. The FEV1 not improve by addition of Accolate. However, when the asthmatic with obstructed lung function (FEV₁ $lt;80%) were enrolled only for analysis, the FEV₁ significantly improved at 3rd (p$lt;0.05) and 6th weeks (p$lt;0.05). In 21 asthmatics, oral prednisolone was continuously used at the beginning of this trial. It could be discontinued in 4 patients and the dosage of prednisolone was significantly reduced in another 3 patients by addition of Accolate. Their mean administered dosage of prednisolone decreased from 8.6±0.9 mg/day to 6.8±1.1 mg/day at the end of this trial (p$lt;0.05).
Conclusions: With these results, we thought that addition of Accolate as a long term control imen in the symptomatic persistent asthmatics would be an effective strategy. For evaluation of steroid sparing effects, further studies will be needed.
|
|
|
KEYWORD
|
|
|
Accolate, Bronchial asthma, Leukotriene antagonist,
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|